Summary
What do they do? SFCCC’s Street Outreach Services describes mobile healthcare, including wound care. This does not establish a sustained venous-ulcer protocol. The model is for clinically assessed, eligible venous disease—not every wound or swollen leg. Federal health-center funding and other clinical providers must be reconciled. More
Why this approach interests us
- Sustained, appropriate venous-ulcer care may produce more time without an ulcer.
Our main reservations
- The treatment trial improved ulcer-free time but not generic health utility. Local protocol and course delivery are unverified.
What do you get for your dollar?
Our provisional best estimate is $2.5M per DALY:one modeled equivalent year. This is a narrow, highly uncertain health-only model, not the organization’s overall impact or a verified donation offer. Inspect the assumptions →
- best guess
- $2.5M — per DALY; conditional donor budget
- positive scenarios
- $55K–$520.0M — Joint scenarios, not confidence intervals
- health evidence
- Null is plausible — A positive best guess does not rule out no added health
- funding room
- Unverified — Public contracts are not marginal donation offers
1. What do they do?
SFCCC’s Street Outreach Services describes mobile healthcare, including wound care. This does not establish a sustained venous-ulcer protocol. The model is for clinically assessed, eligible venous disease—not every wound or swollen leg. Federal health-center funding and other clinical providers must be reconciled.
Verify clinical eligibility
Diagnosis and vascular assessment precede treatment; inappropriate compression in arterial disease can harm.
Fund the complete pathway
Budget weekly care while ulcerated plus aftercare and recurrence prevention, rather than borrowing full-course efficacy for twelve contacts.
Compare actual usual care
Measure health and harms beyond existing services. Offer-level trial effects already contain uptake; do not multiply another generic completion factor.
Scope of this review. Count each patient pathway once. Do not add mortality, housing, substance-use treatment or other overlapping benefits without separate causal models and reconciliation.
2. Monitoring and information sharing
233 eligible patients; mean age about74
Morrell1998 randomized clinical bundle. 5.9 additional ulcer-free weeks over one year; generic EuroQol/SF36 difference absent.
Our assessment. Weekly treatment while ulcerated, then stockings/review. Arterial disease excluded. Weeks already incorporate recurrence; no extra recurrence credit.
Healed and nonhealed venous-ulcer respondents
Small observational health-state comparison. Wong2023 .870 versus.812, p=.39; noncausal and imprecise.
Our assessment. The .05 central and .16 favorable utility gaps are judgments, not established causal effects.
3. Qualitative assessment
Sustained, appropriate venous-ulcer care may produce more time without an ulcer.
Key reservations
- Existing usual care may already deliver effective compression. Clinic location alone is not the active ingredient.
- A short twelve-contact pilot cannot inherit the complete one-year package effect without a separate model.
- No sepsis, amputation or mortality credit is inferred from generic wound-treatment encounters.
Benefits not included in our estimate
- Healthcare savings as donor cash
- Unmodeled mortality reduction
- Independent housing and substance-use benefits
- Unpriced public or volunteered resources
4. What do you get for your dollar?
$2.5M per DALY
Central gross donor cost isUSD3,500 for a full-year pathway.5.9 extra ulcer-free weeks /52 ×.05 assumed utility ×.5 transfer ×.5 financing gives 0.00 QALY. The utility bridge is judgmental; the trial did not demonstrate a generic utility advantage.
DALY is our one-year comparison unit. QALY-based health gains and income-welfare equivalents retain their original assumptions; they are not measured clinical DALYs. These are uncertain estimates, not measured returns or verified donation offers.
How we calculate the estimate
DOLLARS per DALY: course cost / {financing × [ulcer-free weeks /52 ×utility gap ×transfer −extra net harm]}
$2.5M per DALY
Model inputs and assumptions
- Donor full-course cost judgment
- 3500 (range: 1000 / 3500 / 6000). Range order: favorable / central / pessimistic. No verified local marginal price. Analyst judgment.
- Additional ulcer-free weeks within one year
- 5.9 (range: 10.5 / 5.9 / 1.2). Range order: favorable / central / pessimistic. No verified local marginal price. External study anchor; not local effect.
- Causal utility gap judgment
- 0.05 (range: 0.16 / 0.05 / 0.02). Range order: favorable / central / pessimistic. No verified local marginal price. Analyst judgment.
- Clinical context transfer
- 0.5 (range: 0.75 / 0.5 / 0.1). Range order: favorable / central / pessimistic. No verified local marginal price. Analyst judgment.
- Additional delivery attributable to financing
- 0.5 (range: 0.75 / 0.5 / 0.25). Range order: favorable / central / pessimistic. No verified local marginal price. Analyst judgment.
- Extra net harm per additional course
- 0 (range: 0 / 0 / 0). Range order: favorable / central / pessimistic. No verified local marginal price. Analyst judgment.
Hypothetical course budget—not a verified funding tranche
- Favorable full-course: $55K per DALY. 0.01817 conditional QALY per offered course.
- Central: $2.5M per DALY. 0.001418 conditional QALY per offered course.
- Pessimistic: $520.0M per DALY. 0.00001154 conditional QALY per offered course.
Uncertainty. Zero actual utility benefit, unchanged care or fully replaced financing gives no finite positive price. Net harms can make health negative; this is not a negative-price bargain.
5. Funding and previous grants
Need a named clinically eligible cohort, additional capacity, all payer contributions and measured health difference versus actual usual care.
Constructed course:32 planned contacts ×(.5 RN hour ×USD100 ×1.3 loading +USD30 supplies) +USD460 assessment/aftercare/travel/admin =3,500.32 is a planning proxy, not an observed visit count. The460 allowance needs itemization; volunteer/public resources and failed outreach require verification. No donor quote.
This review does not establish a verified marginal funding offer or a complete history of grants.
Opens the organization’s giving page. A general donation may not fund the specific activity modeled here; confirm allocation with the recipient.
6. Sources
- Street Outreach Services. SFCCC. Provider disclosure. Published: Undated; retrieved: 2026-09-07.
- Provider statement on SOS services. SFCCC. Provider-authored release; not outcome evaluation. Published: 2024-12-03; retrieved: 2026-09-07.
- Morrell1998 community leg-ulcer trial. BMJ. Primary randomized trial. Published: 1998; retrieved: 2026-09-07.
- Wong2023 venous-ulcer health utility. Health Science Reports. Noncausal health-state comparison. Published: 2023; retrieved: 2026-09-07.
- Federal programs. SFCCC. Public funding overlap. Published: Undated; retrieved: 2026-09-07.
- Registered Nurse2320 pay scale. City and County of SF. Labor cost orientation, not SOS quote. Published: 2026; retrieved: 2026-09-07.
Annual expenses: years and sources
Average annual expenses (three consecutive fiscal years): $14,909,462. Organization size is separate from the modeled cost-effectiveness of a donation.
San Francisco Community Clinic Consortium
Form 990 reported whole-entity expenses; includes program, administration and fundraising costs, but excludes costs netted against revenue.
Fiscal years ended June 30. Whole consortium filing expenses, including grants; not the combined budgets of member clinics or the Street Outreach Services program alone.